<DOC>
	<DOCNO>NCT02178306</DOCNO>
	<brief_summary>To evaluate safety efficacy , particular regard renal function telmisartan dose 40 mg 80 mg hypertensive patient moderate endstage renal impairment 12 week treatment</brief_summary>
	<brief_title>Efficacy Safety Telmisartan Hypertensive Patients With Mild/Moderate Severe Renal Impairment Requiring Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>1 . Mild moderate hypertension , sit diastolic BP ≥ 90 mmHg BP ≤ 109 mmHg visit 2 2 . No increase serum creatinine 30 % within 6 month trial 3 . Stable renal insufficiency serum creatinine 200 600 µmol/l maintenance hemodialysis 4 . Stable proteinuria least 500 mg/24h 5 . No change hemodialysis regimen within last two month prior visit 1 6 . 18 year age 7 . Ability provide write informed consent accordance good clinical practice local registration 8 . Able stop current antihypertensive therapy ( ACEInhibitors angiotensin II receptor subtype 1 Blocker ) without risk patient 1 . Premenopausal woman ( last menstruation ≤ 1 year prior start runinphase ) : 1. surgically sterile ; and/or 2. nursing 3. childbearing potential NOT practice acceptable mean birth control , NOT plan continue use method throughout study NOT agree submit periodic pregnancy test participation study ≥ 3months duration . Acceptable method birth control include oral , implantable injectable contraceptive 2 . Known suspected renovascular hypertension 3 . Mean sit SBP ≥ 180 mmHg mean sit DBP ≥110 mmHg visit placebo runin phase 4 . Hepatic dysfunction define follow laboratory parameter : serum glutamate pyruvate transaminase ( ALT ) serum glutamate oxaloacetate transaminase ( AST ) &gt; 2 time upper limit normal range 5 . Bilateral renal artery stenosis ; renal artery stenosis solitary kidney , patient postrenal transplant one kidney 6 . Clinically relevant hypo hyperkalaemia 7 . Uncorrected volume depletion 8 . Uncorrected sodium depletion 9 . Primary aldosteronism 10 . Hereditary fructose intolerance 11 . Biliary obstructive disorder 12 . Patients previously experience symptom characteristic angioedema treatment ACE inhibitor angiotensin II antagonists 13 . History drug alcohol abuse within 6 month 14 . Chronic administration medication know affect blood pressure , except medication allow protocol ( ßblocker , alphablocker , calcium antagonist , clonidine , minoxidil , diuretic ) 15 . Any investigational therapy within one month signing informed consent form 16 . Known hypersensitivity component formulation 17 . Has contraindication placebo runin period ( e.g . unstable angina within past 3 month , stroke within past 6 month myocardial infarction cardiac surgery within past 3 month ) 18 . Any clinical condition , opinion investigator , would allow safe completion protocol safe administration telmisartan 19 . Compliance &lt; 70 % runin period ( define pill count ) 20 . History heart failure , malignancy , disorder require immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>